$ANL

Roche (RHHBY) and Teva (TEVA) gained FDA approvals for new treatments. Mesa Labs (MLAB) and GSK (GSK) announced job cuts. Labcorp (LH) and AstraZeneca (AZN) made strategic deals. Vir (VIR) partnered with Gilead (GILD) for cancer immunotherapy. Galderma (GALD.SW) to acquire ZO Skin Health for $1.5B. Zealand Pharma (ZEAL.CO) partnered with Generate Biomedicines for AI drug discovery.

Adlai Nortye (ANL) has partnered with Lilly (LLY) and Merck KGaA (MRCG.DE, MRK.DE) to explore cetuximab in trials with AN4035. Lilly and Merck will supply cetuximab for U.S., Australia, and China sites. ANL shares closed at $10.88 on Nasdaq.

Ji Ping sold 10,214 shares of Adlai Nortye Group Ltd. (ANL) at an average of $15.99 ($15.77–$16.03, $0.16M total) across 3 trades over 2026-09-29 to 2026-09-30.

Ye Xiaofeng (CFO) sold 11,667 shares of Adlai Nortye Group Ltd. (ANL) at an average of $14.11 ($13.98–$14.25, $0.16M total) across 2 trades over 2026-08-24 to 2026-08-26.

Adlai Nortye Ltd. (NASDAQ: ANL) reported unaudited first-half 2026 results and pipeline updates. It said enrollment is ongoing for Phase I AN9025 in QD and QW arms, and it received Australia HREC approval for Phase I AN4035. Cash and short-term investments were $231.9M at June 30, 2026. Net loss fell to $5.3M; revenue rose to $13.1M.

Biotech stocks rose Wednesday. Apollomics (APLM) jumped 22% after Nasdaq closed its MVLS compliance issue. Iovance (IOVA) gained 21% ahead of Q2 results; AVITA Medical (RCEL) rose 18% before Aug. 6 earnings; Annexon (ANNX) climbed 17% ahead of ARCHER II updates. Veradermics (MANE) gained 12% on Phase 2 hair-loss topline results.

Adlai Nortye Ltd. (NASDAQ: ANL) said it expanded its Scientific Advisory Board by appointing Dr. David S. Hong and Dr. Piro Lito. The company links the SAB to guidance for its oncology pipeline, including RAS inhibitor programs AN9025 and AN4035, and immuno-oncology candidate AN8025.

Biotech gainers: Innovative Eyewear (LUCY) rose 63% after preliminary Q2 2026 net sales of ~$0.99M (+71% YoY) and new retail orders; Seer (SEER) jumped 35% on an unsolicited $2.45/share cash takeover proposal plus contingent value rights; Orthofix (OFIX) and Enovis (ENOV) gained 16%/15% after CMS withdrew reimbursement changes for non-invasive bone growth stimulators.

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) has a consensus “Moderate Buy” rating from six covering analysts, MarketBeat reports: one sell and five buy. The average 1-year target price is $24.25. Analysts cited include HC Wainwright ($20), JonesTrading ($22), Cantor Fitzgerald (overweight), Oppenheimer ($32). ANL opened at $10.00 Monday.

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Nov. 21, 2025 ( GLOBE NEWSWIRE ) -- Adlai Nortye Ltd. ( NASDAQ: ANL ) ( the "Company" or "Adlai Nortye" ) , a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that members of ...